357 related articles for article (PubMed ID: 30910382)
21. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
22. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
23. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.
Tang Q; Gu L; Zhou B; Shi J; Wu H; Zhu H; Xu Y; Zhang T
Biopreserv Biobank; 2022 Dec; 20(6):567-574. PubMed ID: 35294840
[TBL] [Abstract][Full Text] [Related]
25. Modulation of chimeric antigen receptor surface expression by a small molecule switch.
Juillerat A; Tkach D; Busser BW; Temburni S; Valton J; Duclert A; Poirot L; Depil S; Duchateau P
BMC Biotechnol; 2019 Jul; 19(1):44. PubMed ID: 31269942
[TBL] [Abstract][Full Text] [Related]
26. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
Mihara K; Yoshida T; Bhattacharyya J
Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
[TBL] [Abstract][Full Text] [Related]
27. Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.
Pajarillo R; Paruzzo L; Carturan A; Ugwuanyi O; White G; Guruprasad P; Ballard HJ; Patel RP; Zhang Y; Lee YG; Hong SJA; Dittami GM; Ruella M
Cytotherapy; 2024 May; 26(5):506-511. PubMed ID: 38483365
[TBL] [Abstract][Full Text] [Related]
28. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
29. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
31. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
32. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
33. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
Xu C; Yin Y
Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
[TBL] [Abstract][Full Text] [Related]
34. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
[TBL] [Abstract][Full Text] [Related]
36. GMP CAR-T cell production.
Gee AP
Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
38. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
39. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
40. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
